Randomised trial of telephone counselling to improve participants' adherence to prescribed drugs in a vascular screening trial
| Autor: | Jesper Hallas, Rikke Søgaard, Ina Qvist, Lars Frost, Jes S. Lindholt, Vibeke Lorentzen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Counseling
Male Health Knowledge Attitudes Practice Time Factors Denmark telephone counselling Toxicology 030226 pharmacology & pharmacy law.invention 0302 clinical medicine Randomized controlled trial law Antithrombotic media_common General Medicine Abdominal aortic aneurysm Drug class Treatment Outcome Hypertension Drug Diagnostic Screening Programs medicine.medical_specialty Statin medicine.drug_class media_common.quotation_subject Drug Prescriptions Medication Adherence 03 medical and health sciences Peripheral Arterial Disease Fibrinolytic Agents Internal medicine medicine Humans Medical prescription Antihypertensive Agents Aged Pharmacology business.industry screening Cardiovascular Agents medicine.disease Telephone cardiovascular diseases Blood pressure medication adherence Hydroxymethylglutaryl-CoA Reductase Inhibitors business randomised controlled trial 030217 neurology & neurosurgery Aortic Aneurysm Abdominal |
| Zdroj: | Qvist, I, Lindholt, J S, Søgaard, R, Lorentzen, V, Hallas, J & Frost, L 2020, ' Randomised trial of telephone counselling to improve participants' adherence to prescribed drugs in a vascular screening trial ', Basic and Clinical Pharmacology and Toxicology, vol. 127, no. 6, pp. 477-487 . https://doi.org/10.1111/bcpt.13459 |
| DOI: | 10.1111/bcpt.13459 |
| Popis: | A total of 1446 participants, 65- to 74-year-old men diagnosed with abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD) or high blood pressure (HB) in the Viborg Vascular (VIVA) screening trial, were consecutively included and randomised to a telephone counselling (TC) or no TC 3 months after being screened positive. Data from VIVA were linked to data from Danish registers from 2007 to 2016. The primary outcome was a composite outcome of proportion of days covered by statin, antithrombotic drugs and antihypertensive agents and for each specific drug class at 6-month follow-up. The same outcomes were assessed at 12 and 60 months and considered secondary outcomes. Outcome measures are reported as risk differences (RD). There were no differences between the groups in relation to the composite of all three drug classes over 6 months of follow-up, RD = 4.1 (95% CI: −1.0; 9.1). A significant increase in redeemed statin prescriptions was observed in the intervention group at 6 months, RD = 9.8% (CI 95%: 0.5; 19.0). There was no intervention effect observed after 12 and 60 months. TC 3 months after screening improved adherence to statin at 6-month follow-up, but had no effect on the composite treatment, statins, antithrombotic or antihypertensive treatment over 60 months of follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|